Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Viardot

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Der Pathologe|October 28, 2020
[Perspectives on CAR T-cell treatment]Andreas Viardot
Expert Opinion on Investigational Drugs|May 17, 2021
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemiaAndreas Viardot, Elisa Sala
Cancer Treatment Reviews|April 11, 2018
Bispecific antibodies in haematological malignanciesAndreas Viardot, Ralf Bargou
Cancer Management and Research|May 23, 2019
Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucelAndreas Viardot, Verena Wais, Elisa Sala, et al.
Expert Opinion on Pharmacotherapy|February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literatureAlexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Annals of Hematology|August 29, 2020
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapiesAndreas Viardot, Franco Locatelli, Julia Stieglmaier, et al.
Experimental Hematology|July 6, 2021
Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomabVirginie Nägele, Gerhard Zugmaier, Maria-Elisabeth Goebeler, et al.
Mutagenesis|May 9, 2009
Micronuclei in peripheral blood from patients after cytostatic therapy mainly arise ex vivo from persistent damageNicole Sibel Arsoy, Simone Neuss, Swen Wessendorf, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 8, 2020
Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphomaLaila König, Klaus Herfarth, Juliane Hörner-Rieber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 19, 2009
Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagementDorit Fabricius, Marina Neubauer, Birgit Mandel, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Der Pathologe|October 28, 2020
[Perspectives on CAR T-cell treatment]Andreas Viardot
Expert Opinion on Investigational Drugs|May 17, 2021
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemiaAndreas Viardot, Elisa Sala
Cancer Treatment Reviews|April 11, 2018
Bispecific antibodies in haematological malignanciesAndreas Viardot, Ralf Bargou
Cancer Management and Research|May 23, 2019
Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucelAndreas Viardot, Verena Wais, Elisa Sala, et al.
Expert Opinion on Pharmacotherapy|February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literatureAlexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Annals of Hematology|August 29, 2020
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapiesAndreas Viardot, Franco Locatelli, Julia Stieglmaier, et al.
Experimental Hematology|July 6, 2021
Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomabVirginie Nägele, Gerhard Zugmaier, Maria-Elisabeth Goebeler, et al.
Mutagenesis|May 9, 2009
Micronuclei in peripheral blood from patients after cytostatic therapy mainly arise ex vivo from persistent damageNicole Sibel Arsoy, Simone Neuss, Swen Wessendorf, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 8, 2020
Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphomaLaila König, Klaus Herfarth, Juliane Hörner-Rieber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 19, 2009
Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagementDorit Fabricius, Marina Neubauer, Birgit Mandel, et al.
Pageof 9